[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-cancer-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-cancer-adult":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,38,67,95,131,159,182,201,228,253,277,304,333,350,374,406,425,474,499,525],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100645246","risk-stratification-and-proactive-nursing-intervention-for-acute-kidney-injury-following-interventional-therapy-in-patients-with-liver-cancer-100645246",false,"NCT07681817","Risk Stratification and Proactive Nursing Intervention for Acute Kidney Injury Following Interventional Therapy in Patients With Liver Cancer","Inclusion Criteria:\n\n* Completed eligibility screening in Phase I of the study\n* Completed AKI risk assessment using the established prediction model\n* Classified by the model as at risk for AKI (moderate- or high-risk patients prioritized; low-risk patients included only for exploratory\u002Fobservational analysis)\n* Conscious and able to communicate effectively\n* Able to understand and comply with nursing interventions\n* Expected hospital stay of at least 3 days\n* Available for postoperative follow-up\n* Provided written informed consent jointly with a primary caregiver\n\nExclusion Criteria:\n\n* Development of AKI within 24 hours after interventional therapy according to KDIGO criteria\n* Severe psychiatric disorders, cognitive impairment, or communication barriers preventing participation in HBM-based assessment or intervention\n* Requirement for postoperative ICU admission and continuous life-support therapy\n* Mandatory use of nephrotoxic medications that cannot be discontinued, substituted, or adjusted during the study period\n* Participation in other clinical intervention studies that may affect renal function or nursing outcomes","ALL","18 Years",{"count":18,"type":19},200,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study focuses on the early identification and precision prevention of acute kidney injury (AKI) following interventional therapy in patients with liver cancer. A prospective, phased mixed-methods research design will be adopted. In the first phase, a prospective cohort study will be conducted to systematically collect clinical and nursing-related data. A Super Learner ensemble algorithm will be employed to develop and validate an AKI risk prediction model, enabling precise risk stratification of patients. In the second phase, a prospective randomized controlled trial will be implemented. Guided by the Health Belief Model (HBM), a risk-stratified proactive nursing intervention will be delivered, and its effectiveness will be compared with that of routine nursing care in reducing the incidence of AKI, improving adherence to hydration protocols, optimizing the management of nephrotoxic medications, and enhancing patients' self-management capabilities. By integrating intelligent risk prediction with proactive nursing intervention strategies, this study aims to establish a reproducible and scalable precision prevention and management model for AKI in liver cancer patients undergoing interventional therapy. The findings are expected to provide scientific evidence for early AKI warning and proactive nursing practice, thereby promoting the precision, intelligence, and standardization of oncologic interventional nursing care.",[25],"Liver Cancer, Adult","NOT_YET_RECRUITING","2026-06-30",{"date":29,"type":30},"2026-07-02","ACTUAL",{"date":32,"type":19},"2026-07-01",{"date":34,"type":19},"2028-12-31",{"name":36,"class":37},"Tianjin Medical University Cancer Institute and Hospital","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":20,"phases":47,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":66},"100645279","phase-2-utilize-imaging-to-assess-changes-in-hepatocellular-carcinoma-perfusion-as-potentiated-by-intra-arterial-nitroglycerin-100645279","NCT07682454","Utilize Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin","Utilizing Parenchymal Blood Volume Imaging to Assess Changes in Hepatocellular Carcinoma Perfusion as Potentiated by Intra-Arterial Nitroglycerin","Inclusion Criteria:\n\n1. Participants must have radiographically documented, previously untreated LIRADS V liver lesions or biopsy-confirmed hepatocellular carcinoma (HCC), as determined by the ZSFG Liver Tumor Board.\n2. Lesions must be determined to be suitable for conventional trans-arterial chemoembolization (cTACE) based on multidisciplinary tumor board review.\n3. No prior locoregional therapy (e.g., TACE, Y-90) to the index lesion(s).\n4. Age ≥18 years.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky \\>70%)\n6. Demonstrates adequate organ function as defined below:\n\n   1. Absolute neutrophil count \\>=1,500\u002Fmicroliter (mcL).\n   2. Platelets ≥100,000\u002Fmicroliter (mcL).\n   3. Total bilirubin ≤ 3.0 milligrams per deciliter (mg\u002FdL), unless elevated due to Gilbert's syndrome and direct bilirubin is within normal limits.\n   4. Aspartate aminotransferase (AST) \u002F serum glutamic-oxaloacetic transaminase (SGOT) ≤3 X institutional upper limit of normal.\n   5. Alanine aminotransferase (ALT) \u002F serum glutamic-oxaloacetic transaminase (SGPT) ≤3 X institutional upper limit of normal\n   6. Creatinine ≤ 1.5 x within institutional upper limit of normal or\n   7. Creatinine clearance Glomerular filtration rate (GFR) \\>= 60 milliliters per minute (mL\u002Fmin)\u002F1.73 m2, calculated using the Cockcroft-Gault equation, unless data exists supporting safe use at lower kidney function values, no lower than 30 milliliters per minute (mL\u002Fmin)\u002F1.73 m2.\n7. Liver function: Child-Pugh score must be no higher than B5.\n8. Ability to understand and the willingness to sign a written informed consent document.\n9. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n10. The female participants of childbearing potential and male participants with partners of childbearing potential must agree to use effective contraception during the study and for 30 days after study intervention.\n\nExclusion Criteria:\n\n1. Multifocal disease (i.e., presence of more than one HCC lesion).\n2. Has received systemic anticancer therapies within 3 weeks of first dose, radiation within 2 weeks, antibody therapy within 4 weeks. Concomitant administration of LHRH analogues for prostate cancer and somatostatin analogues for neuroendocrine tumors are allowed as per standard of care.\n3. Has not recovered from adverse events due to prior anti-cancer therapy to ≤ grade 1 or baseline (other than alopecia).\n4. Is currently receiving any other therapeutic\u002Finvestigational agents.\n5. Has participated in a study of an investigational product and received study treatment or used an investigational device within 3 weeks of the first use of an investigational product.\n6. Co-morbid disease or concurrent illness (e.g., cardiovascular disease, portal vein thrombosis).\n7. Hypersensitivity to nitroglycerine or any of its excipients.\n8. Concomitant medications (contraindicated):\n\n   1. Concurrent use of prescription phosphodiesterase inhibitors (e.g., sildenafil)\n   2. Concurrent use of nitrate-containing medications.\n   3. Concurrent use of vasoactive chemotherapeutic agents, such as bevacizumab (Avastin).\n9. Recent anti-cancer therapies:\n\n   1. Systemic anticancer therapies within 3 weeks of the procedure.\n   2. Radiation therapy within 2 weeks.\n   3. Antibody-based therapy within 4 weeks.\n   4. Use of investigational agents or devices within 3 weeks of the index procedure.\n10. Unresolved toxicities from prior cancer therapy, unless ≤ Grade 1 (excluding alopecia).\n11. Currently receiving any other therapeutic or investigational agents during the study period.",{"count":46,"type":19},50,[48],"PHASE2","This is a single-arm, open-label, single-center, first-in-human feasibility study evaluating parenchymal blood volume (PBV) imaging as a tool to dynamically assess perfusional changes in hepatocellular carcinoma (HCC) potentiated by intra-arterial administration of nitroglycerin.",[51,25],"Hepatocellular Carcinoma (HCC)",[53,54,55,56,57],"Parenchymal Blood Volume Imaging","Transarterial Chemoembolization","Intra-Arterial Nitroglycerin","Tumor Perfusion","TACE","2026-06-26",{"date":29,"type":30},{"date":61,"type":19},"2026-08-01",{"date":63,"type":19},"2030-02-01",{"name":65,"class":37},"University of California, San Francisco",2,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":20,"phases":76,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100579490","time-restricted-eating-and-healthy-eating-in-patients-with-metabolic-liver-disease-or-cancer-100579490","NCT06824974","Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer","Feasibility Study of Time Restricted Eating and a Healthy Diet in Patients Receiving Liver-Directed Therapy for Hepatocellular Carcinoma","TRE+HE","Inclusion Criteria:\n\n1. Overweight or obese (BMI 27-45 kg\u002Fm2)\n2. Diagnosed with metabolic-dysfunction associated steatitic liver disease (MASLD\u002FNAFLD), metabolic-dysfunction associated steatohepatitis, cirrhosis or liver cancer (BCLC early to intermediate stage HCC)\n3. English or Spanish speaking over the age of 18.\n4. ECOG Performance Status ≤ 2.\n5. Usual nightly fasting \\\u003C12 hours\n6. Willing to comply with all study procedures\n7. Life expectancy of \\> 12 months\n\nExclusion Criteria:\n\n1. Advanced HCC, progression, and\u002For associated comorbidities\n2. Metastatic disease, tumor in vein, or ascites\n3. Advanced Cirrhosis (hypoalbuminemia\u002FChild-Pugh B+C).\n4. Poorly controlled or refractory (grade 3-4) hepatic encephalopathy\n5. Type 1 diabetes or self-reported hypoglycemia or hypoglycemic events by CGM\n6. Participation in another conflicting study that requires modification of diet or food timing.\n7. Patients on GLP-1 receptor agonists\n8. Uncontrollable eating pattern (e.g., wasting, Night Eating Syndrome, disordered eating habits, food insecurity)\n9. Medications that markedly impact metabolic study biomarkers.\n10. Other cancer in last 10 years (other than nonmelanoma skin cancer or carcinoma of the cervix in situ)\n11. Serious medical conditions such as chronic kidney disease, congestive heart failure, or any condition that would interfere with participation in the trial.\n12. Unresolved toxicity ≥ CTCAE Grade 2 from previous anti-cancer therapy\n13. Active alcohol abuse or less than 6 months of sobriety\n14. Participation in a trial of an investigational agent within the prior 30 days\n15. Pregnancy or lactating, positive hCG urine test.",{"count":46,"type":19},[22],"This is a feasibility study that will collect data to assess the potential effect of nutritional intervention. This prospective single-site trial will enroll adult patients with liver diseases such as metabolic-dysfunction associated steatotic liver disease (MASLD), metabolic-dysfunction associated steatohepatitis (MASH), cirrhosis and\u002For hepatocellular carcinoma (HCC). Eligible individuals who are randomized to the intervention group will be enrolled in a six-month nutritional change program consisting of time-restricted eating plus targeted healthy changes in what they eat (TR-HE). The intervention includes dietary counseling visits with a study registered dietitian (RD) and motivational phone calls with a study Certified Health and Wellness Coach (HC). Individuals who are randomized to the control group or who elect to join the control group will be enrolled in a six-month period of observation and phlebotomy only. The main questions it aims to answer are:\n\nIs a prolonged nightly fast coupled with a healthy diet safe and feasible for patients with liver disease or cancer? Does the intervention improve liver metabolism?",[25,79,80],"MASH - Metabolic Dysfunction-Associated Steatohepatitis","Obesity and Overweight",[82,83],"Time-restricted eating","healthy diet","RECRUITING","2026-06-22",{"date":87,"type":30},"2026-06-25",{"date":89,"type":30},"2025-08-01",{"date":91,"type":19},"2028-12",{"name":93,"class":37},"University of California, San Diego",1,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":20,"phases":105,"briefSummary":107,"conditions":108,"keywords":112,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":130},"100428822","phase-1-gpc3-targeted-t-cell-therapy-ect204-in-adults-with-advanced-hcc-100428822","NCT04864054","GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC","An Open-Label, Dose Escalation, Multi-Center Phase I\u002FII Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC)","ARYA-3","Inclusion Criteria:\n\n* Histologically confirmed HCC, that is unresectable, recurrent, and\u002For metastatic.\n* GPC3-positive tumor expression confirmed by immunohistochemistry (IHC).\n\n  * For the dose-escalation cohort: ≥10-20% tumor cells, ≥2+ IHC.\n  * Beginning with the RP2D confirmatory cohort: ≥ 50% tumor cells, 2+\u002F3+ IHC.\n* Must have received at least first-line systemic therapy for HCC and have experienced disease progression on, or intolerance to, that therapy.\n* Life expectancy of at least 4 months per the Investigator's opinion.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* Measurable disease by RECIST v1.1.\n* Child-Pugh score of A6 or better.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Pre-existing illness (e.g., symptomatic congestive heart failure) that would limit compliance with study requirements.\n* Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with Human Immunodeficiency Virus (HIV), hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.\n* History of malignancy other than HCC within 5 years before screening, except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other malignancies with low risk of recurrence.\n* Known brain metastases or other active central nervous system (CNS) involvement, including leptomeningeal disease. Subjects with brain metastases that have been adequately treated (no evident neurological deficit and no steroid or anti-epileptic therapy for brain metastases) are eligible.\n* Pregnant or lactating women.\n* Currently receiving or ending (\\\u003C 14 days from date of consent) liver tumor-directed therapy (e.g., radiation, ablation, embolization), or hepatic surgery.\n* Concurrently receiving other investigational agents, biological, chemical, or radiation therapies, while participating in the study.\n* Active autoimmune disease requiring systemic immunosuppressive therapy.\n* Presence of portal vein tumor thrombus (PVTT) classified as grade Vp4, or any invasion into the inferior vena cava (IVC), except for subjects with IVC invasion who have been treated and radiographically stable for at least 6 months prior to screening.\n* Ascites requiring active treatment, such as a requirement for paracentesis or escalation of diuretic doses. Exception: Subjects maintained on a stable dose of diuretics with controlled, asymptomatic ascites are eligible.\n* Active gastrointestinal (GI) bleeding event ≥ Grade 3 per National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE), version 5.0, within 6 months prior to screening.\n* Coagulation abnormality defined as international normalized ratio (INR) \\> 1.7, unless the elevation is due to therapeutic anticoagulation that, in the Investigator's judgment, can be safely managed in the context of study procedures.\n* History of organ transplant.\n* HCC involving greater than 50% of the liver volume.\n* Experienced allergies to any component of the study drug (ECT204), mouse immunoglobulin, or iron-dextran, or have a history of severe hypersensitivity, including anaphylaxis.\n* Previously received other gene therapy (e.g., chimeric antigen receptor T-cell \\[CAR-T\\] therapy); exception: prior oncolytic virus therapy is permitted.).\n* Contraindication for undergoing leukapheresis procedure or receipt of conditioning agents",{"count":104,"type":19},60,[106,48],"PHASE1","This is an open-label, multi-center, Phase 1\u002F2 clinical trial evaluating the safety, tolerability, and efficacy of ECT204, an investigational ARTEMIS® T-cell therapy, in adult subjects with GPC3-positive hepatocellular carcinoma (HCC) who have experienced disease progression on, or intolerance to, prior systemic therapy.",[109,25,110,111],"Hepatocellular Carcinoma","Liver Neoplasm","Metastatic Liver Cancer",[109,113,114,115,110,111,116,117,118,119],"Advanced HCC","Late-Stage HCC","Liver Cancer","Metastatic HCC","T-cell therapy","Immunotherapy","HCC","2026-06-05",{"date":122,"type":30},"2026-06-09",{"date":124,"type":30},"2022-03-11",{"date":126,"type":19},"2027-12-31",{"name":128,"class":129},"Eureka Therapeutics Inc.","INDUSTRY",8,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":20,"phases":141,"briefSummary":142,"conditions":143,"keywords":146,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":94},"100616951","phase-2-radioembolization-with-intra-arterial-angiotensin-ii-to-improve-tumor-absorbed-dose-radiant-100616951","NCT07312292","Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)","Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose","RADIANT","Inclusion criteria:\n\n* Patients diagnosed with primary or metastatic liver tumors (any histological type).\n* A clinical indication for radioembolization.\n* Liver tumors with a diameter ≥ 2 cm.\n* Age ≥ 18 years.\n* Competent and able to provide own informed consent (no legally designated representative).\n* Written informed consent.\n\nExclusion criteria:\n\n* Any serious comorbidity preventing the safe administration of angiotensin II (AT-II). This includes:\n\n  1. Uncontrolled hypertension.\n  2. Treatment with ≥ 3 antihypertensive drugs.\n  3. Arterial (cerebro-)vascular or venous thromboembolic event within the past 6 months.\n* Current use of angiotensin-converting enzyme (ACE) inhibitors.\n* Current use of angiotensin II receptor blockers (ARBs).\n* Known hypercoagulable state (i.e., thrombophilia).\n* History of severe peripheral vascular disease.\n* Known hypersensitivity to the active substance in Giapreza: angiotensin II.\n* Known hypersensitivity to any of the excipients in Giapreza: mannitol, sodium hydroxide or hydrochloric acid.\n* Any serious and\u002For chronic liver disease preventing the safe administration of radioembolization.\n* Uncorrectable extrahepatic deposition of scout dose activity; activity in the falciform ligament, portal lymph nodes, and gallbladder is accepted.\n* Pregnancy or breastfeeding.\n* Body weight over 150 kg (because of maximum table load).\n* Known severe allergy to intravenous contrast fluids.\n* Participation in another investigational study which may compromise any endpoint of the study.\n* Any other significant comorbidity or medical condition that may compromise the safety of radioembolization.",{"count":140,"type":19},15,[48],"This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better. The drug is given directly into the artery that supplies blood to the liver, right before a treatment called yttrium-90 (90Y) radioembolization.\n\nThe main questions it aims to answer are:\n\n* Does angiotensin II help more of the radioactive beads reach the tumor and less reach the healthy parts of the liver?\n* Is it safe to add angiotensin II to the standard radioembolization treatment? What will participants do?\n* First visit (work-up): Participants will have the standard preparation for radioembolization. A small test dose of radioactive tracer technetium 99mTc macroaggregated albumin (99mTc-MAA) will be injected into the liver through an artery. On the same day, a single-photon emission computed tomography (SPECT)\u002FCT scan will be performed to see how the tracer distributes in the liver and if there are depositions outside the liver. If everything looks good, the participant will return for treatment in 2-3 weeks.\n* Second visit (treatment): Participants will receive the actual radioembolization treatment. At each injection site in the liver, first angiotensin II is administered, immediately followed by the injection of the radioactive beads (90Y microspheres). If the treatment requires injections in multiple locations, the participant will receive angiotensin II at each spot.\n* After treatment: Participants will receive a Positron Emission Tomography (PET)\u002FCT scan so the research team can see where the radioactive beads went. This will be compared to the distribution of the radioactive tracer (99mTc-MAA) from the first SPECT\u002FCT scan (performed without angiotensin II) to measure how much angiotensin II helped target the tumor.\n\nAll monitoring (including blood pressure, heart rate, oxygen saturation, and breathing rate) takes place during the procedure as part of routine care, and there are no extra hospital visits beyond what is normally required for radioembolization.",[144,145],"Liver Cancer (Locally Advanced or Metastatic)","Liver Cancer Adult",[147,148,149],"Radioembolization","Angiotensin II","yttrium-90","2026-03-24",{"date":152,"type":30},"2026-03-30",{"date":154,"type":30},"2026-01-01",{"date":156,"type":19},"2027-11-01",{"name":158,"class":37},"Niek Wijnen",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":180,"locationsCount":181},"100493443","development-of-3d-multi-parametric-ultrasound-mpus-as-a-decision-support-tool-for-patients-100493443","NCT05705219","Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients","Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients With Abdominal and Pelvic Tumors Undergoing Therapy","3DMPUS","Inclusion Criteria:\n\n1. Participant has untreated liver metastases from colorectal low-grade adenocarcinoma (biopsy-proven and\u002For characteristic findings on CT, MRI, or FDG-PET) and has planned to undergo a new course of cancer therapy\\*.\n2. Participant is age \\>\u002F=18 years.\n3. Participant has at least one target lesion that measures ≥1cm in diameter (minimum size according to RECIST 1.1) with a maximum diameter of 14cm amenable to imaging with ultrasound\n4. Participant is willing to comply with protocol requirements.\n5. Participant has given written informed consent to participate in this study.\n\n   * Any line of cancer therapy is allowed, including systemic and localized treatments, after any prior treatment. For systemic combination treatments, prior treatment with either drug is allowed at the discretion of the investigators, including rechallenges with the same drug combination, for example upon progression on imaging after a treatment break. For combination treatments where patients start treatment with different drugs at different times, the start date of treatment is determined at the discretion of the investigators and can be the start date of the first drug or of the combination treatment. Repeat participation in the study is allowed, if patients are eligible again per their treatment plan.\n\nExclusion Criteria:\n\n1. Participant has documented anaphylactic or other severe reaction to any ultrasound contrast media or polyethylene glycol (PEG).\n2. Participant has any comorbid condition\\*\\* that, in the opinion of the treating provider or the Protocol Director, compromises the participant's ability to participate in the study.\n3. Participant is pregnant (positive urine or serum beta-hCG) or lactating.\n4. Presence of cardiac shunt or presence of pulmonary hypertension (contradiction for ultrasound contrast agent)\n5. Renal insufficiency with a creatinine level \\>1.5mg\u002Fdl, per our institutional guidelines (contradiction for CT imaging).\n\n   * Examples: any mental condition that compromises the ability to follow a consent discussion, or to make informed decisions (except if represented by a Legally Authorized Representative \\[LAR\\]); any condition that makes the participant not a good candidate to have ultrasound exams with contrast agent.",{"count":168,"type":19},80,"OBSERVATIONAL","This clinical trial studies how well 3-dimensional multi-parametric ultrasound (3D MPUS) imaging works as a decision-support tool for patients with liver tumors undergoing therapy. Continuous and dynamic imaging of patients undergoing therapy is required to monitor early-phase treatment response.",[25],[173],"Diagnostic Study","2026-01-22",{"date":176,"type":30},"2026-01-26",{"date":178,"type":30},"2023-12-04",{"date":34,"type":19},{"name":93,"class":37},3,{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":199,"locationsCount":5},"100619486","radiation-segmentectomy-with-resin-microspheres-raserem-study-100619486","NCT07345247","RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study","RASEREM","Inclusion Criteria:\n\n* Patients aged ≥18 years\n* Underwent RE as a RS intent (have single or \\\u003C3 tumors in same or neighboring 2 segments) for the treatment of HCC or metastatic tumor to liver.\n* Presence of extrahepatic disease\n* Tumor size less than 8 cm\n* Child Pugh Score \\\u003CB9\n\nExclusion Criteria:\n\n* Presence of macrovascular invasion,\n* Presence of extrahepatic disease,\n* Cholangiocarcinoma or mixed HCC-cholangiocarcinoma\n* Not willing to attend follow-up visits.",{"count":190,"type":19},150,"Radiation segmentectomy (RS) refers to selective infusion of Y-90 microspheres to the tumor bearing hepatic segment of hepatic artery. Majority of the data on RS is based on the Glass microspheres experience. Due to different properties of Resin and Glass microspheres description of dose limits to the segment for effectiveness of treatments with Resin microspheres are needed.\n\nBased on this background in this study it is aimed to evaluate the safety and efficacy of RS with resin microspheres in HCC patients. Secondly, it is planned to describe the dose limits for complete radiological response.",[25],[115,147],"2026-01-20",{"date":174,"type":30},{"date":89,"type":30},{"date":198,"type":19},"2028-08-01",{"name":200,"class":37},"Ankara University",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":20,"phases":211,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":226,"locationsCount":94},"100617111","phase-2-fad-subtype-guided-combination-therapy-for-unresectable-hepatocellular-carcinoma-100617111","NCT07314372","FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","A Prospective Phase II Study of Fatty Acid Degradation (FAD) Subtype-Guided Comprehensive Therapy for Unresectable Hepatocellular Carcinoma","FAD-HCC-001","Inclusion Criteria:\n\n1. Adults ≥18 years of age who voluntarily agree to participate and sign informed consent.\n2. Histologically or cytologically confirmed hepatocellular carcinoma (HCC).\n3. Unresectable or not suitable for curative local therapy, or progression after prior surgery or local therapy.\n4. BCLC stage B or C.\n5. No prior systemic therapy for HCC.\n6. At least one measurable lesion according to RECIST v1.1.\n7. Availability of fresh or archival tumor tissue for FAD subtype testing; if not available at screening, MRI fat fraction may be used temporarily.\n8. Child-Pugh class A or B (≤7 points).\n9. ECOG performance status 0-1.\n10. Adequate organ function, including:\n\n    * ANC ≥1.5 × 10⁹\u002FL\n    * Platelets ≥75 × 10⁹\u002FL\n    * Hemoglobin ≥90 g\u002FL\n    * Albumin ≥30 g\u002FL\n    * Total bilirubin ≤1.5 × ULN\n    * ALT and AST ≤3 × ULN\n    * Serum creatinine ≤1.5 × ULN or creatinine clearance \\>50 mL\u002Fmin\n    * INR ≤1.2 or PT within 2 seconds above ULN\n    * Urine protein \\\u003C2+ or 24-hour urine protein \\\u003C1.0 g\n11. Controlled HBV infection (HBV-DNA \\\u003C2000 IU\u002FmL; if above this level, ≥1 week of antiviral therapy with ≥1-log reduction prior to first dose). HCV-positive individuals must be managed per clinical guidelines.\n12. Life expectancy ≥12 weeks.\n13. Women of childbearing potential must have a negative pregnancy test; participants of reproductive potential must agree to effective contraception during treatment and for 6 months afterward.\n\nExclusion Criteria:\n\n1. Non-HCC primary liver cancers (e.g., cholangiocarcinoma, combined HCC-CCA).\n2. F3 subtype without liver lesions on imaging.\n3. Clinically significant ascites requiring therapeutic intervention, or uncontrolled pleural\u002Fpericardial effusion.\n4. Interstitial lung disease, pneumonitis requiring steroids, or active pulmonary infection.\n5. Active or history of autoimmune disease requiring systemic treatment (exceptions allowed per protocol, e.g., controlled hypothyroidism).\n6. Recent use (within 2 weeks) of systemic immunosuppressive therapy \\>10 mg\u002Fday prednisone equivalent.\n7. Gastrointestinal bleeding within 6 months, high-risk varices, active ulcers, fistula, perforation, or intra-abdominal abscess.\n8. Known bleeding or clotting disorders; therapeutic anticoagulation not permitted.\n9. Thromboembolic events within 6 months (e.g., stroke, PE).\n10. Significant cardiovascular disease, including NYHA class ≥II heart failure, recent MI (within 1 year), unstable angina, clinically significant arrhythmias, or QTc prolongation.\n11. Uncontrolled hypertension (SBP ≥140 mmHg or DBP ≥90 mmHg despite treatment), or history of hypertensive crisis.\n12. Major vascular disease within 6 months (e.g., arterial thrombosis, aneurysm requiring repair).\n13. Serious non-healing wounds, active ulcers, or fractures.\n14. Inability to swallow oral medication or conditions affecting drug absorption.\n15. Severe infection within 4 weeks, therapeutic antibiotics within 14 days, fever ≥38.5°C within 7 days before enrollment, or WBC \\>15 × 10⁹\u002FL.\n16. Known HIV infection or other causes of immunodeficiency.\n17. Receipt of live attenuated vaccines within 28 days before treatment.\n18. Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of results, including substance abuse, severe psychiatric illness, or social factors.",{"count":210,"type":19},86,[48],"This study is a prospective, multicenter Phase II trial evaluating a personalized treatment strategy for patients with unresectable hepatocellular carcinoma (HCC). The study uses a metabolic classification system called the fatty acid degradation (FAD) subtype to guide therapy selection. Patients will be assigned to different treatment groups based on their tumor's FAD subtype, determined through RNA-seq analysis of the tumor tissue obtained from liver biopsy.",[214,51,145],"Unresectable Hepatocellular Carcinoma (HCC)",[109,216,217,218,219,118,220,57],"Fatty Acid Degradation","Metabolic Subtyping","Precision Medicine","Conversion Therapy","Anti-angiogenic Therapy","2026-01-16",{"date":194,"type":30},{"date":224,"type":19},"2026-02-01",{"date":91,"type":19},{"name":227,"class":37},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":94},"100617208","an-innovative-cfd-based-dosimetry-and-pre-treatment-planning-platform-to-support-personalized-transarterial-therapies-for-liver-cancer-100617208","NCT07315633","An Innovative CFD-based Dosimetry and Pre-treatment Planning Platform to Support Personalized Transarterial Therapies for Liver Cancer","Inclusion Criteria:\n\n* Subjects radiologically diagnosed with HCC, eligible for or undergoing treatment.\n* Subjects who are treated (or will be treated) using TARE with radioactive microspheres.\n* Subjects for whom pre-treatment medical imaging of the hepatic arterial vasculature was performed for TARE planning (e.g., CT, MRI, PET, SPECT, and DSA), which can be used to develop patient-specific 3D models of the hepatic arterial tree and treatment dose distribution.\n\nExclusion Criteria:\n\n* Subjects undergoing TARE procedures without adequate medical imaging of the hepatic vasculature.\n* Subjects in whom no pre- or post-treatment imaging data are available for analysis.",{"count":168,"type":19},"Transarterial radioembolization (TARE) is a key treatment option for patients with unresectable hepatocellular carcinoma (HCC), a primary form of liver cancer. TARE is a minimally invasive therapy in which radioactive microspheres are delivered through a microcatheter near the tumour into the liver's blood vessels. Although TARE can significantly improve survival, treatment outcomes remain variable and difficult to predict, mainly because of complex liver vasculature and unpredictable distribution of radioactive microspheres due to uncertain parameters such as catheter tip location, catheter orientation, and injection velocity.\n\nThe long-term goal would be to make these treatments more predictable and effective by developing a patient-specific pre-treatment planning platform. Blood flow and microsphere transport will be modelled in a digital model of the patient-specific hepatic arterial tree (based on clinical imaging) using computational fluid dynamics (CFD), in combination with Monte Carlo-based radiation dosimetry. Using CFD simulations, we will investigate how variations in treatment parameters influence the microsphere distribution, aiming to better understand their role in treatment variability. This will allow us to predict the dose distribution of a certain treatment and determine potentially a more optimal set of treatment parameters. This research contributes to the broader field of cancer research by laying the foundations for a digital tool for personalized pre-treatment planning. The insights gained could support interventional radiologists in optimizing treatment planning, improving tumor targeting, and minimizing radiation exposure to healthy liver tissue in future TARE procedures.",[51,25,115],[238,239,240,241,242,243],"Hepatocellular carcinoma","Transarterial radioembolization","Computational Fluid Dynamics","Personalized medicine","Pre-treatment planning","Monte Carlo Dosimetry calculations","2025-12-18",{"date":246,"type":30},"2026-01-02",{"date":248,"type":30},"2025-09-23",{"date":250,"type":19},"2030-12-31",{"name":252,"class":37},"University Hospital, Ghent",{"id":254,"slug":255,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":20,"phases":263,"briefSummary":265,"conditions":266,"keywords":267,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":273,"leadSponsor":275,"locationsCount":94},"100615642","early-phase-1-nir-ii-fluorescence-guided-hepatectomy-using-icg-cisplatin-nanoprobes-for-hcc-100615642","NCT07295262","NIR-II Fluorescence-Guided Hepatectomy Using ICG-Cisplatin Nanoprobes for HCC","ICG-Cisplatin Self-Assembled Nanoprobes for Near-Infrared-Il Fluorescence Imaging-Guided Liver Resection","Inclusion Criteria:\n\n1. Age 18-75 years.\n2. First diagnosis of Hepatocellular Carcinoma (HCC) (non-recurrent).\n3. Single tumor with diameter ≤ 5 cm.\n4. Assessed as resectable by more than 2 senior liver surgeons (experience \\>10 years, \\>500 hepatectomies).\n5. No distant metastasis on preoperative chest CT and abdominal contrast-enhanced CT.\n6. Child-Pugh Class A liver function.\n7. Patient or legal guardian able to understand the study and sign informed consent.\n\nExclusion Criteria:\n\n1. Postoperative pathology confirms cholangiocarcinoma, sarcomatoid HCC, combined HCC-ICC, or fibrolamellar carcinoma.\n2. Presence of portal vein, hepatic vein, or bile duct tumor thrombus.\n3. History of other malignancies (except cured carcinoma in situ of cervix, basal cell carcinoma, or squamous cell skin carcinoma).\n4. Evidence of residual lesion, recurrence, or metastasis during preoperative assessment; or postoperative pathology confirming lymph node metastasis or positive margins.\n5. Moderate to severe ascites requiring therapeutic paracentesis\u002Fdrainage, or Child-Pugh score \\> 7 (except for small amount of ascites on imaging without clinical symptoms).\n6. Uncontrolled or moderate\u002Flarge amount of pleural effusion or pericardial effusion.\n7. Severe cardiac, pulmonary, or renal dysfunction.\n8. Ruptured HCC requiring emergency surgery.\n9. Patient or family unable to understand the study conditions and objectives.","75 Years",{"count":262,"type":19},30,[264],"EARLY_PHASE1","This prospective, single-arm exploratory study evaluates the feasibility and safety of a novel ICG-Cisplatin self-assembled nanoprobe (NIR-II NanoM) for fluorescence-guided surgery in patients with Hepatocellular Carcinoma (HCC). Participants will receive a transarterial injection of the nanoprobe mixed with lipiodol prior to surgery. During the subsequent laparoscopic anatomic hepatectomy, surgeons will utilize a Near-Infrared II (NIR-II) imaging system to visualize tumor boundaries and liver segments for precise resection.",[25],[268],"liver cancer","2025-12-07",{"date":271,"type":30},"2025-12-19",{"date":154,"type":19},{"date":274,"type":19},"2028-12-01",{"name":276,"class":37},"West China Hospital",{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":20,"phases":286,"briefSummary":287,"conditions":288,"keywords":291,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":94},"100611178","15-vs-45-minute-pringle-maneuver-in-liver-cancer-resection-randomized-noninferiority-trial-100611178","NCT07237204","15 vs 45 Minute Pringle Maneuver in Liver Cancer Resection: Randomized Noninferiority Trial","A Prospective, Randomized Noninferiority Trial Comparing 15- and 45-minute Pringle Maneuvers During Liver Resection for Oncologic Indications.","Inclusion Criteria:\n\n* Diagnosis of a primary or secondary malignant liver tumor.\n* Age \\> 18 years.\n* Patient deemed eligible for liver resection.\n* WHO performance status ≤ 2.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Liver cirrhosis.\n* Liver dysfunction classified as Child-Pugh class B or C.\n* Repeat hepatectomy.\n* Prior ablation or chemoembolization of hepatic lesions.\n* Prior portal vein branch embolization.\n* Planned or performed ALPPS procedure.\n* Concomitant resection of any organ other than the gallbladder during the same operation.",{"count":285,"type":19},600,[22],"The goal of this clinical trial is to evaluate the safety of two durations of the Pringle maneuver in adults undergoing elective liver resection for malignant tumors. The main questions it aims to answer are:\n\nIs the incidence of post-hepatectomy liver failure different between 15-minute and 45-minute Pringle maneuver durations?\n\n* Do the durations differ in operative time or intraoperative blood loss?\n* Researchers will compare patients randomized 1:1 to 15 minutes vs 45 minutes of Pringle clamping to see if outcomes are non-inferior between groups.\n\nParticipants will:\n\n* Undergo standard oncologic hepatectomy with the assigned Pringle duration.\n* Receive routine perioperative assessments, including laboratory tests and clinical evaluations.\n* Attend follow-up visits at approximately 6 months, 1 year, and 3 years after surgery.",[25,289,290],"Metastases to Liver","Liver Malignant Tumors",[292,293,294],"Pringle manouver","Liver malignancy","Liver resection","2025-11-14",{"date":297,"type":30},"2025-11-19",{"date":299,"type":19},"2025-12-01",{"date":301,"type":19},"2030-11-01",{"name":303,"class":37},"Medical University of Warsaw",{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":310,"eligibilityCriteria":311,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":312,"targetDuration":4,"studyType":20,"phases":313,"briefSummary":314,"conditions":315,"keywords":318,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":325,"startDateStruct":327,"completionDateStruct":329,"leadSponsor":331,"locationsCount":94},"100607668","international-study-on-treatment-of-patients-with-metastatic-colorectal-liver-lesions-patients-with-ire-100607668","NCT07191548","International Study on Treatment of Patients With Metastatic Colorectal Liver Lesions Patients With IRE","Treatment of LIVER METastases From Colorectal Cancer by IRreversible Electroporation: A Prospective, International, Multi-centre Cohort Study.","LIVERMET-IRE","Inclusion Criteria:\n\n* Patients aged 18 years and over, able to provide informed consent and with histological confirmation of a diagnosis of colorectal cancer from primary tumour.\n* Liver lesions demonstrating radiological characteristics (on magnetic resonance scan) of colorectal hepatic metastases without requirement for biopsy. In the setting of an intact liver, patients with up to four metastases ≤ 4cm in size are eligible for inclusion. In the setting of proposed resection plus ablation, up to two metastases ≤ 4cm in size. In the setting of recurrence after prior hepatectomy up to two metastases ≤ 4cm in size.\n* Eastern Co-operative Oncology Group (ECOG) Score ≤ 2.\n* Rockwood Frailty Score ≤ 3.\n* Serum bilirubin \\\u003C 30 µmol\u002FL.\n* Serum creatinine \\\u003C 150 µmol\u002FL.\n* Up to two lung metastases (\\\u003C 2cm in size permitted at enrolment).\n* Prior treatment with at least one course of systemic chemotherapy (± biologic agent) mandated. Chemotherapy protocol is not specified and is at clinician discretion.\n* Primary rectal tumour can remain in situ treated with radiotherapy\u002Fchemoradiotherapy according to tumour board recommendations. Primary colonic tumour can remain in situ.\n* No prior hepatic tumour ablation\n\nExclusion Criteria:\n\n* Patients involved in other research studies.\n* Inability to give informed consent.\n* Patients who are pregnant.\n* Accepted exclusions to IRE from consensus criteria including:\n* Platelet count \\\u003C 50x109 U\u002FL.\n* International normalised ratio (INR) for blood clotting \\> 1.7.\n* Prior hepatic tumour ablation.\n\nCardiovascular fitness related exclusions:\n\n* History of ventricular arrhythmia.\n* Implanted pacemaker or defibrillator.\n* Congestive cardiac failure NYHA Class ≥ 3.\n\nTumour-related exclusions:\n\n* Tumour ≥ 4 cm in size.\n* Advanced multi-site metastatic cancer (any of the following): peritoneal metastases (M1c), bone metastases, \\> 2 lung metastases, all segment involvement multiple liver metastases.\n* Jaundice (serum bilirubin \\> 30 µmol\u002FL).\n* MDT\u002Ftumour recommends use of thermal ablation instead of IRE for any given lesion.",{"count":46,"type":19},[22],"Procedural data will be recorded from patients with liver metastases from colorectal cancer who have received at least one course of systemic chemotherapy and who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation.",[316,317,25],"Colorectal Adenocarcinoma Metastatic in the Liver","Liver Ablation",[319,320,321,322,323],"irreversible electroporation","liver ablation","metastatic liver disease","nanoknife","liver ire registry","2025-10-08",{"date":326,"type":30},"2025-10-10",{"date":328,"type":19},"2026-02",{"date":330,"type":19},"2029-02",{"name":332,"class":129},"Angiodynamics, Inc.",{"id":334,"slug":335,"hasResults":11,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":339,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":20,"phases":342,"briefSummary":343,"conditions":344,"keywords":345,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":324,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":348,"leadSponsor":349,"locationsCount":94},"100607759","international-study-on-treatment-of-liver-hcc-patients-with-ire-100607759","NCT07192731","International Study on Treatment of Liver (HCC) Patients With IRE","Treatment of LIVER-limited HepatoCellular Carcinoma (HCC) in Patients With Preserved Liver Function by IRreversible Electroporation: A Prospective, International, Multi-centre Cohort Study","LIVERHCC-IRE","Inclusion Criteria:\n\n* Patients aged 18 years and over, able to provide informed consent and with clinical diagnosis of an HCC. Tissue confirmation of HCC prior to treatment is not standard of care and is therefore not required for this study.\n* Child-Pugh A up to A6.\n* Eastern Co-operative Oncology Group (ECOG) Score ≤ 2.\n* Rockwood Frailty Score ≤ 3.\n* Serum bilirubin \\\u003C 30 µmol\u002FL.\n* Serum creatinine \\\u003C 150 µmol\u002FL.\n* No extrahepatic metastases\n* IRE can be used for up to 3 tumours \\\u003C 3cm in size. Other forms of ablation can be combined with IRE in the same sitting but not for the same lesion. IRE can also be combined with surgical resection.\n\nExclusion Criteria:\n\nGeneral:\n\n* Patients involved in other research studies.\n* Patients under the age of 18 years.\n* Inability to give informed consent.\n* Patients who are pregnant.\n* Child-Pugh B or C.\n* Patients with an ECOG status of \\> 2 at time of recruitment.\n* Rockwood Frailty Score \\> 3\n* Impaired renal function (serum creatinine \\> 150 µmol\u002FL)\n* Accepted exclusions to IRE from consensus criteria including:\n* Platelet count \\\u003C 50x109 U\u002FL.\n* International normalised ratio (INR) for blood clotting \\> 1.7.\n* Prior hepatic tumour ablation.\n\nCardiovascular fitness related exclusions:\n\n* History of ventricular arrhythmia.\n* Implanted pacemaker or defibrillator.\n* Congestive cardiac failure NYHA Class ≥ 3.\n\nTumour-related exclusions:\n\n* Tumour ≥ 3 cm in size.\n* Extrahepatic metastatic disease.\n* Jaundice (serum bilirubin \\> 30 µmol\u002FL).\n* MDT recommends use of thermal ablation for any given lesion.",{"count":46,"type":19},[22],"Procedural data will be recorded from patients with liver lesions from hepatocellular cancer who have been assessed by an appropriately constituted MDT (or equivalent) as appropriate to receive irreversible electroporation",[51,317,25],[319,320,322,323],{"date":326,"type":30},{"date":328,"type":19},{"date":330,"type":19},{"name":332,"class":129},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":20,"phases":359,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":365,"lastUpdatePostDateStruct":366,"startDateStruct":368,"completionDateStruct":370,"leadSponsor":372,"locationsCount":94},"100568483","novel-method-to-assess-hepatic-regeneration-and-predict-hepatic-related-morbidity-after-partial-hepatectomy-100568483","NCT06681818","Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy","Postoperative Heme Oxygenase Induction and Carbon Monoxide Production as a Novel Method to Assess Hepatic Regeneration and Predict Hepatic Related Morbidity After Partial Hepatectomy","Inclusion Criteria:\n\n* Patient plans to have partial liver resection for primary liver pathology or metastatic disease\n* Patient is able to comprehend and willing to sign the written consent form\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years\n* Patients identified as members of a vulnerable population, except women of child bearing potential with negative pregnancy test",{"count":358,"type":19},125,[22],"the investigators will pursue two specific aims: (1) to monitor the extent of heme oxygenase induction (by measuring endogenous CO production) in relationship to the extent of hepatic resection (2) to assess the production of CO in patients following liver resection and correlate these findings to the rate of liver regeneration and liver function.",[145,362],"Liver Regeneration",[364],"hepatectomy","2025-07-18",{"date":367,"type":30},"2025-07-23",{"date":369,"type":19},"2025-11-21",{"date":371,"type":19},"2039-01-01",{"name":373,"class":37},"Englewood Hospital and Medical Center",{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":383,"conditions":384,"keywords":391,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":94},"100598351","digital-early-warning-system-for-acute-lung-injury-in-liver-surgery-100598351","NCT07070362","Digital Early Warning System for Acute Lung Injury in Liver Surgery","The Construction of a Digital Intelligence Early Warning System for the Whole Process of Acute Lung Injury in Liver Surgery Based on Cardiopulmonary Interaction Characteristics","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing major liver surgery (including two-segment or more hepatectomy, liver transplantation, etc.)\n* Voluntary participation with signed informed consent",{"count":382,"type":19},4000,"This study focuses on developing an explainable machine learning model based on cardiopulmonary interaction characteristics to achieve early prediction of acute lung injury (ALI) in patients undergoing major liver surgery. The research will establish a digital early-warning system for ALI to provide support for clinical diagnosis and treatment decisions, thereby reducing the incidence and fatality rate of ALI.",[385,386,387,388,389,390,25],"Acute Lung Injury(ALI)","Liver Cirrhosis","ARDS, Human","MASLD","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","NAFLD (Nonalcoholic Fatty Liver Disease)",[392,393,394,395,396],"Digital Intelligence","Acute Lung Injury","PPCs","Liver Surgery","Cardiopulmonary Interaction;","2025-07-08",{"date":399,"type":30},"2025-07-17",{"date":401,"type":30},"2024-11-01",{"date":403,"type":19},"2027-11-30",{"name":405,"class":37},"Beijing Tsinghua Chang Gung Hospital",{"id":407,"slug":408,"hasResults":11,"nctId":409,"briefTitle":410,"officialTitle":410,"acronym":4,"eligibilityCriteria":411,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":412,"targetDuration":4,"studyType":169,"phases":4,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":419,"completionDateStruct":421,"leadSponsor":423,"locationsCount":4},"100597173","the-diagnostic-efficacy-and-lesion-detection-advantages-of-18f-fdg-petcontrast-enhanced-mri-in-malignant-liver-lesions-100597173","NCT07055048","The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET\u002FContrast-enhanced MRI in Malignant Liver Lesions","Inclusion Criteria:\n\n* Age ≥18 years;\n* Patients with suspected liver metastases or hepatic lesions,\n* Ability to undergo 18F-FDG PET\u002FMRI examination;\n* Willingness to comply with study protocols.\n\nExclusion Criteria:\n\n* Patients with a history of allergic reactions to MRI contrast agents;\n* Pregnant or lactating women;\n* Patients with severe comorbidities, including: Cardiac disease，Renal failure，or Hepatic failure (Child-Pugh C);\n* Patients unable to cooperate with PET\u002FMRI procedures.",{"count":104,"type":19},"Liver disease, a major global health burden, ranges from mild dysfunction to severe conditions like cirrhosis and hepatocellular carcinoma (HCC), the fifth most common cancer. Accurate diagnosis of liver lesions-distinguishing benign from malignant-is vital for treatment planning. Conventional imaging (ultrasound, CT, MRI) has limitations in sensitivity and detecting small metastases. PET\u002FCT combines metabolic and anatomical data but struggles with small lesions and cirrhotic livers.\n\n18F-FDG PET\u002FMRI with contrast-enhanced MRI may improve diagnostic accuracy, but its clinical benefits remain uncertain. Further research is needed to evaluate its performance, impact on patient outcomes, and cost-effectiveness in liver disease management.",[25],[416,268],"PET\u002FMR","2025-07-03",{"date":397,"type":30},{"date":420,"type":19},"2025-06-30",{"date":422,"type":19},"2025-12-31",{"name":424,"class":37},"Shanghai East Hospital",{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":432,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":433,"targetDuration":434,"studyType":169,"phases":4,"briefSummary":435,"conditions":436,"keywords":453,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":473},"100579293","raman-spectroscopy-based-deep-learning-model-for-early-pan-cancer-early-diagnosis-100579293","NCT06822413","Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","A Novel Raman Spectroscopy-Based Method for Pan-Cancers Early Diagnosis Supported by Deep Learning: A Prospective, Single-Arm, Multicentre Study","Inclusion Criteria:\n\n* Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.\n* Patients in normal physiological conditions without any malignant tumors or precancerous lesions.\n* Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.\n* Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.\n\nExclusion Criteria:\n\n* Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time\n* Post-cancer treatment patients.",true,{"count":285,"type":19},"1 Year","The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are:\n\n* Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk.\n* Identifying which model is more adaptable to the Raman spectrum\n* Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.",[437,25,438,439,440,441,442,443,444,445,446,447,448,449,450,451,452],"Cancer Diagnosis","Cancer Screening","Colorectal Cancer (CRC)","Gastric Cancers","Normal Physiology","Pancreatic Cancer, Adult","Raman Spectroscopy","Deep Learning Model","Esophageal Cancer","Malignant Tumours","Precancerous Conditions","Pancreatitis","Adenoma Colon Polyp","Gastric Ulcer","Oesophagitis","Cirrhoses, Liver",[454,455,438,443,456,457,458,445,459,460,448,461,462,451,463],"Pan-cancer","Deep Learning Models","Colorectal Cancer","Pancreatic Cancer","Gastric Cancer","malignant tumour","Precancerous Condtions","Colorectal Adenoma","Gastirc Ulcer","Cirrhoses","2025-04-19",{"date":466,"type":30},"2025-04-24",{"date":468,"type":30},"2022-09-01",{"date":470,"type":19},"2025-07-28",{"name":472,"class":37},"Second Affiliated Hospital, School of Medicine, Zhejiang University",4,{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":4,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":260,"enrollmentInfo":481,"targetDuration":4,"studyType":20,"phases":483,"briefSummary":484,"conditions":485,"keywords":487,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":497,"locationsCount":4},"100454265","phase-2-study-of-hbv-tcr-t-cells-liocyx-m-as-monotherapy-or-as-combination-with-lenvatinib-for-hbv-related-hcc-100454265","NCT05195294","Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCC","A Multi-center, Phase 2 Study for Autologous T Cells Transfected With mRNA Encoding HBV Antigen-specific TCR (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for Advanced HBV-related Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n2. Advanced HCC with diagnosis confirmed by histology\u002F cytology or clinically by AASLD criteria in cirrhotic patients.\n3. Disease that is not amenable to curative surgical and\u002For locoregional therapies, or progressive disease after surgical and \u002For locoregional therapies\n4. Patients who failed first-line systemic therapy for HCC\n5. Serum HBsAg positivity\n6. Non-cirrhotic or compensated cirrhosis Child-Pugh A (5 - 6 points)\n7. HLA class 1 profile matching HLA-class I restriction element of the available T cell receptor\n\nExclusion Criteria:\n\n1. Brain metastasis\n2. Second primary malignancy that is clinically detectable at the time of consideration for study enrolment, except for in situ carcinoma of the cervix, non-melanoma skin carcinoma localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer and superficial bladder tumours.\n3. Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples\n4. History of severe allergic anaphylactic reactions to T cell therapy products and\u002For lenvatinib\n5. Local or loco-regional therapy of intrahepatic tumour lesions (e.g. surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or cryoablation) must have been completed ≥4 weeks before the first infusion of LioCyx-M.\n6. Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, tyrosine kinase inhibitor therapy, and immunotherapy.\n7. Treatment with anticancer therapy, including investigational therapy, within 2 weeks prior to first infusion. For prior therapies with a half-life longer than 3 days, discontinuation of the therapy must have occurred at least 28 days prior to leukapheresis.\n8. Treatment with other investigational therapy within 28 days prior to initiation of study treatment. Patients participating in surveys or observational studies are eligible to participate in this study.\n9. Likelihood to require any immunosuppressive treatments during the period of the clinical trial (Localized steroid use should be allowed)\n10. Human immunodeficiency virus (HIV) positive or active infection requiring treatment (except for HBV)\n11. Significant cardiovascular disease (such as New York Heart Association (NYHA) Functional Classification Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment), unstable arrhythmia, or unstable angina\n12. Uncontrolled hypertension, defined as systolic blood pressure \\>160 mmHg or diastolic pressure \\>110 mmHg, despite optimal medical management",{"count":482,"type":19},55,[48],"This is an open-label and multi-center Phase 2 study to evaluate the safety and efficacy of autologous T-cells transfected with mRNA encoding Hepatitis-B virus (HBV)-antigen-specific T cell receptor (TCR) (LioCyx-M) as monotherapy or as combination with lenvatinib for the treatment of advanced HBV-related hepatocellular carcinoma (HCC).",[109,25,486],"Liver Cell Carcinoma",[488,109,489,490],"TCR T cells","HBV","Hepatitis B virus","2025-03-05",{"date":493,"type":30},"2025-03-10",{"date":495,"type":19},"2025-03",{"date":91,"type":19},{"name":498,"class":129},"Lion TCR Pte. Ltd.",{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":505,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":507,"targetDuration":509,"studyType":169,"phases":4,"briefSummary":510,"conditions":511,"keywords":512,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":94},"100575849","immunophenotype-of-pbmc-to-early-predict-response-to-immunotherapy-in-hepatocellular-carcinoma-100575849","NCT06777628","Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma","Immunophenotype of Peripheral Blood Mononuclear Cells to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma","Immunecheck","Inclusion Criteria:\n\n* age ≥ 18 years\n* diagnosis of HCC\n* execution of laboratory tests and subsequent treatments and follow-up at our center.\n* obtained written informed consent to the study participation\n\nExclusion Criteria:\n\n* immune-related concomitant diseases\n* HIV infection",{"count":508,"type":19},100,"3 Years","The study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for:\n\n* predicting response to immune-therapeutic regimens in HCC in the early phase of treatment,\n* to rule out pseudo-progression,\n* to early predict the escape from effectiveness of treatment.",[25],[513,514,515],"immunophenotype","HCC patients","immunotherapy","2025-01-14",{"date":518,"type":30},"2025-01-16",{"date":520,"type":30},"2024-09-15",{"date":522,"type":19},"2028-10-15",{"name":524,"class":37},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":526,"slug":527,"hasResults":11,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":531,"eligibilityCriteria":532,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":533,"targetDuration":4,"studyType":20,"phases":535,"briefSummary":536,"conditions":537,"keywords":540,"overallStatus":84,"whyStopped":4,"lastUpdateSubmitDate":546,"lastUpdatePostDateStruct":547,"startDateStruct":549,"completionDateStruct":551,"leadSponsor":553,"locationsCount":94},"100569076","phase-1-mts105-for-advanced-hepatocellular-carcinoma-100569076","NCT06689540","Mts105 for Advanced Hepatocellular Carcinoma","First-in-human Clinical Study of Mts105 for Advanced Hepatocellular Carcinoma","MTS105 for HCC","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC), excluding fibrolamellar or sarcomatoid subtypes, as well as mixed hepato-cholangiocellular carcinoma;\n2. Positive for GPC3 expression per immunohistochemical (IHC) staining.\n3. Failure of standard systemic therapies, including at least one immune checkpoint inhibitor and one targeted therapy (Tyrosine Kinase Inhibitors, and\u002For anti vascular endothelial growth factor agent).\n4. Presence of a measurable tumor lesion (per RECIST\u002F mRECIST criteria).\n5. Barcelona Clinical Liver Cancer Stage B or C (BCLC B\u002FC)\n6. Child-Pugh Score ≤ 6\n7. ECOG score ≤ 1\n8. Adequate organ and bone marrow function as defined by the following laboratory criteria:\n\n   1. Hematology: No blood transfusion or colony-stimulating factor therapy within 7 days prior to the first dose. The following hematological parameters should be met:Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL;Lymphocyte count ≥ 0.5 × 10\\^9\u002FL;Hemoglobin ≥ 90 g\u002FL;Platelet count ≥ 75 × 10\\^9\u002FL;\n   2. Liver function:Total bilirubin ≤ 2.5 mg\u002FdL;Albumin ≥ 28 g\u002FL;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × ULN;\n   3. International Normalized Ratio (INR) ≤ 2.3;Oral anticoagulant therapy at a stable dose for at least 2 weeks. If oral warfarin is used, the patient must have an INR ≤ 3.0 and no bleeding events within 28 days prior to administration;\n   4. Renal function:Serum creatinine ≤ 1.5 × ULN, or endogenous creatinine clearance ≥ 45 mL\u002Fmin (as determined by the CKD-EPI formula);Urinary protein \\\u003C 2+, or urinary protein ≥ 2+ but with 24-hour protein quantification ≤ 1.0 g\n   5. Cardiac function:Left ventricular ejection fraction (LVEF) ≥ 50%; No clinically significant abnormal ECG findings (chronic atrial fibrillation is allowed, provided it does not require medication);\n9. Capable of full communication with the investigator, with the ability to understand and comply with study requirements, and able to understand and sign the informed consent form (ICF).\n10. ≥18 years\n\nExclusion Criteria:\n\n1. Any known active intracranial metastases, or brain metastases that have been treated for less than 4 weeks.\n2. Recent Antitumor Therapy:\n\n   1. Treatment with any immune checkpoint inhibitor within 4 weeks (28 days) prior to the first dose.\n   2. Received any investigational drug within 4 weeks prior to the first dose.\n   3. Received localized therapy for hepatocellular carcinoma (HCC), including but not limited to arterial chemoembolization (TACE), arterial infusion chemotherapy (HAIC), Y-90 radioembolization, ablative therapy, or stereotactic radiation therapy (SBRT), within 4 weeks prior to the first dose.\n   4. Received other anticancer therapies, such as multi-targeted tyrosine kinase inhibitors (mTKIs) and\u002For anti-VEGF therapies, within 3 weeks.\n   5. Received non-specific immunomodulatory therapy, including but not limited to interleukin, interferon, thymidine, etc., within 2 weeks prior to the first dose.\n   6. Received herbal or proprietary Chinese medicine for antitumor indications within 1 week prior to the first dose.\n   7. Previously received experimental treatment targeting GPC3 (patients may be enrolled if they remain positive for GPC3 upon testing).\n3. History of liver transplantation or hematopoietic stem cell transplantation.\n4. Unresolved toxicity from prior anticancer therapy (\\> grade 1, according to CTCAE v5.0).\n5. Major surgery (other than biopsy) within 28 days prior to the first dose.\n6. Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 90 mmHg).\n7. Class III-IV heart failure by New York Heart Association (NYHA) criteria within 6 months prior to the first dose, unstable angina, myocardial infarction, bypass surgery, stent placement, cerebral infarction, or clinically significant valvular heart disease.\n8. QTcF ≥ 450 ms in men and ≥ 470 ms in women (by Fridericia formula).\n9. Severe infection within 4 weeks before the first dose (excluding viral hepatitis), or any signs or symptoms of active infection within 2 weeks before the first dose, or patients requiring antibiotic treatment within 2 weeks (excluding local medications and prophylactic antibiotics); unexplained fever \\> 38.5°C before the first dose.\n10. For HBV-associated HCC:\n\n    1. HBsAg (+) : less than 2 weeks of HBV antiviral standard treatment before the first administration of study drug, with an HBV DNA viral load ≥ 1000 IU\u002FmL.\n    2. HBcAb (+) , HBsAg (-): HBV DNA viral load ≥ 1000 IU\u002FmL.\n11. Hepatitis C virus-infected subjects who have not completed 4 weeks of antiviral treatment.\n12. Positive for human immunodeficiency virus (HIV+).\n13. Subjects requiring systemic corticosteroids (equivalent dose of prednisone \\> 10 mg\u002Fday) or other immunosuppressive drugs within 14 days prior to the first dose or during the study.\n14. History of autoimmune disease requiring systemic treatment within 2 years prior to the first dose.\n15. History of other malignancies within 2 years prior to the first dose (excluding cured skin basal cell carcinoma or squamous cell carcinoma, cervical carcinoma in situ, breast ductal carcinoma in situ, or other cancers that the investigator believes are cured and have an extremely low risk of recurrence).\n16. Women who are pregnant or breastfeeding.\n17. Any other condition that, in the opinion of the investigator, makes participation in the study inappropriate.",{"count":534,"type":19},14,[106],"This is the first-in-human trial of MTS105 (mRNA-LNP). The goal of this clinical trial is to evaluate the safety, tolerability of intravenous injection of MTS105 in advanced hepatocellular carcinoma.",[25,538,539,51],"Metastatic Liver Cancers","HCC - Hepatocellular Carcinoma",[541,542,543,544,545],"hcc","mts105","metis","mRNA","LNP","2024-12-19",{"date":548,"type":30},"2024-12-24",{"date":550,"type":30},"2024-11-18",{"date":552,"type":19},"2026-12-31",{"name":554,"class":37},"Shen Lin"]